Overview

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder

Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the effectiveness of NOE-105 on speech fluency without the known antipsychotic-induced side effects of commonly used treatments for childhood onset fluency disorder (COFD).
Phase:
Phase 2
Details
Lead Sponsor:
Noema Pharma AG